| Literature DB >> 19206012 |
Hideaki Ohta1, Yoshiko Hashii, Akihiro Yoneda, Sachiko Takizawa, Shigenori Kusuki, Sadao Tokimasa, Masahiro Fukuzawa, Akihiro Tsuboi, Ayako Murao, Yoshihiro Oka, Yusuke Oji, Katsuyuki Aozasa, Shin-ichi Nakatsuka, Haruo Sugiyama, Keiichi Ozono.
Abstract
Immunotherapy using a Wilms tumor (WT1) peptide has been undergoing clinical trials for adulthood leukemia and solid cancer with promising results. In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma. She received weekly intradermal injection with HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs). A high proportion of WT1-specific CTLs with effector or effector memory phenotype were detected in peripheral blood of this patient. She is currently still on continued WT1 peptide immunotherapy in a disease-free condition for 22 months. WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19206012 DOI： 10.1080/08880010802435500
Source DB: PubMed Journal: Pediatr Hematol Oncol ISSN： 0888-0018 Impact factor: 1.969